Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, Sensyne Health, Evotec and OSI create new partnership called LAB10x to accelerate data-driven drug discovery powered by AI

Innovation Research

LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at Oxford University.

Sensyne Health, the British clinical artificial intelligence (AI) technology company, today announces that it has entered into a new strategic partnership with Evotec, a global drug discovery and development company, with Oxford University, Oxford University Innovation (OUI) and Oxford Sciences Innovation, the world’s largest IP investment company dedicated to a single university, aimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into breakthrough digital therapeutics, clinical AI algorithms and to accelerate data-driven drug discovery and development.

Read more (Oxford University Innovation website)

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

Cognitive behavioural therapy: we discovered a data gap on its effectiveness for different ethnic groups

General Research

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.